OliX Pharmaceuticals Inc banner
O

OliX Pharmaceuticals Inc
KOSDAQ:226950

Watchlist Manager
OliX Pharmaceuticals Inc
KOSDAQ:226950
Watchlist
Price: 207 000 KRW 5.45% Market Closed
Market Cap: ₩4.2T

Relative Value

The Relative Value of one OliX Pharmaceuticals Inc stock under the Base Case scenario is hidden KRW. Compared to the current market price of 207 000 KRW, OliX Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OliX Pharmaceuticals Inc Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
OliX Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
OliX Pharmaceuticals Inc
KOSDAQ:226950
4.2T KRW 409 -96.2 -117.8 -109.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
407.9B USD 6.7 97.4 16 22.2
US
Amgen Inc
NASDAQ:AMGN
197.9B USD 5.4 25.7 14.8 14.8
US
Gilead Sciences Inc
NASDAQ:GILD
178.6B USD 6.1 21 13.1 16.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 9.6 29.3 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.4B USD 5.6 17.8 13.3 15.2
AU
CSL Ltd
ASX:CSL
70.5B AUD 3.2 35.8 11.8 14.8
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
37.8B EUR 10.8 34.7 37.6 38.4
P/S Multiple
Revenue Growth P/S to Growth
KR
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Average P/S: 3 063 040
409
50%
8.2
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.8
27%
0.4
P/E Multiple
Earnings Growth PEG
KR
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Average P/E: 37.4
Negative Multiple: -96.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
97.4
97%
1
US
Amgen Inc
NASDAQ:AMGN
25.7
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.3
16%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
AU
CSL Ltd
ASX:CSL
35.8
10%
3.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
34.7
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Average EV/EBITDA: 18.4
Negative Multiple: -117.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
14.8
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
37.6
50%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Average EV/EBIT: 20.6
Negative Multiple: -109.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.8
3%
4.9
US
Gilead Sciences Inc
NASDAQ:GILD
16.2
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.8
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
38.4
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett